The firm is exploring a path forward for its gene-editing drug for chronic granulomatous disease, after saying last year it ...

The companies will use Ascidian Therapeutics' RNA exon-editing tech to develop treatments for undisclosed monogenic kidney diseases.

The firm said it will use the funds to study WAY-103 in gastric and pancreatic tumors and advance its AI and spatial biology discovery platform.

At ASCO, researchers shared that in the persevERA trial, giredestrant didn't improve outcomes for first-line advanced breast ...

Analysis of samples from the NATALEE trial, presented at ASCO, revealed some response-linked gene-expression patterns, but ...

Eli Lilly announced a deal to buy the Boston biotech Kelonia for up to $7 billion last month after early results made a ...

The firm's share price jumped 15 percent following the full readout of the Phase III trial, which showed efficacy in those ...

Data presented at ASCO showed that patients who achieved at least 80 percent KRAS G12C ctDNA clearance experienced prolonged survival.

The firm will advance rugonersen, a drug previously developed and then dropped by Roche, into a pivotal Phase III trial.

In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.

CHICAGO – Grail's stock price fell by as much as 16 percent on Monday after results from two trials of its Galleri multi-cancer early detection test were reported at the American Society of Clinical ...

CHICAGO – Eli Lilly's Retevmo (selpercatinib) could be a new option for patients with non-small cell lung cancer to prevent recurrence after surgery, according to data that the company already ...